About

Supeena Adler is an Adjunct Associate Professor of Ethnomusicology at the UCLA Herb Alpert School of Music. She is a native Thai and Lao speaker and a Thai musician who performs and teaches classical Thai music on traditional stringed instruments. Her scholarly interests include mediums, healing rituals, and music in Northeast Thailand and Southern Laos, as well as Okinawa minyo. Adler earned her Ph.D. in Music (Ethnomusicology) from U.C. Riverside, where her dissertation focused on Thai royal musical traditions, nationalism, and Thai royal authority, under the guidance of Professor Deborah Wong. She also holds a master's degree in Southeast Asian Studies: Text, Ritual, and Performance from U.C. Riverside and a B.F.A. in Thai Classical Music from Mahasarakham University in Thailand. Adler is active as a scholar, teacher, and performer of Thai traditional music, and she works as a professional interpreter for Thai and Lao languages. She was responsible for repairing and restoring the Thai musical instrument collection at UCLA and directed the event 'Music of Thailand at UCLA' to celebrate this restoration, with support from the Department of Ethnomusicology and the Center for Southeast Asian Studies. She has obtained support from the Thai Royal Embassy to expand the Thai instrument collection at UCLA. During her time at U.C. Riverside, she established and directed ensembles focused on Thai classical music and Okinawa minyo, involving students, faculty, and community members. In San Diego, she has collaborated with the Thai community to develop curricula for Thai language and culture instruction at a local Thai Buddhist temple, where she has volunteered for over a decade to teach Thai traditional music and perform regularly. Additionally, she has established a professional ensemble of Thai musicians in Southern California, which has performed at venues including the Mingei International Museum in San Diego.

Research topics

• Medicine
• Internal medicine
• Endocrinology
• Pathology
• Computer Science
• Immunology
• Urology
• Artificial Intelligence
• Intensive care medicine
• Gastroenterology
• Pharmacology
• Anatomy

Selected publications

• Favorable Long-Term Outcome in Steroid- and Cyclosporine-Resistant, Tacrolimus-Responsive FSGS

  Journal of the American Society of Nephrology · 2025-10-01

  articleSenior author
  PublisherDOI

• Calcific Changes in an End-Stage Kidney following Long-Term Dialysis, Tertiary Hyperparathyroidism, and Treatment for Complement-Mediated Thrombotic Microangiopathy: A Case Report

  Glomerular Diseases · 2025-08-19

  articleOpen access

  Introduction: There are few descriptions of glomerular calcification in patients with advanced or end-stage kidney disease (ESKD). There also are limited data on long-term outcomes for patients receiving complement factor 5 inhibitor (C5i) treatment for complement-mediated thrombotic microangiopathy (CM-TMA), previously termed atypical hemolytic uremic syndrome, associated with a complement factor I (CFI) mutation. Case Presentation: Here we report a case of ESKD from CM-TMA in a patient who developed tertiary hyperparathyroidism. Due to cerebral symptoms (focal paresthesias) of TMA, he received long-term treatment with a C5i. A nephrectomy subsequently was performed for renal cell carcinoma and showed diffuse glomerular, in addition to focal arterial and tubular basement membrane, calcification. There also was chronic TMA associated with continued C5i treatment, with no evidence of recurrent thrombosis consistent with quiescent systemic TMA activity. Conclusion: Glomerular calcification is rare, and it is unknown if this is related to the treated hyperparathyroidism or other pathogenetic mechanisms. The nephrectomy findings also suggest that patients with pathogenic mutations in CFI may benefit from long-term, likely lifelong, complement inhibitory treatment.

  PublisherOA PDFDOI

• Importance of Integrating Clinical, Serological, Morphological, and Genetic Data to Optimize Care and Prognostication for Patients with Glomerular Diseases

  Journal of the American Society of Nephrology · 2024-10-01

  articleSenior author
  PublisherDOI

• Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today

  Kidney International · 2024-01-18 · 23 citations

  articleOpen access

  Glomerular diseases are classified using a descriptive taxonomy that is not reflective of the heterogeneous underlying molecular drivers. This limits not only diagnostic and therapeutic patient management, but also impacts clinical trials evaluating targeted interventions. The Nephrotic Syndrome Study Network (NEPTUNE) is poised to address these challenges. The study has enrolled >850 pediatric and adult patients with proteinuric glomerular diseases who have contributed to deep clinical, histologic, genetic, and molecular profiles linked to long-term outcomes. The NEPTUNE Knowledge Network, comprising combined, multiscalar data sets, captures each participant’s molecular disease processes at the time of kidney biopsy. In this editorial, we describe the design and implementation of NEPTUNE Match, which bridges a basic science discovery pipeline with targeted clinical trials. Noninvasive biomarkers have been developed for real-time pathway analyses. A Molecular Nephrology Board reviews the pathway maps together with clinical, laboratory, and histopathologic data assembled for each patient to compile a Match report that estimates the fit between the specific molecular disease pathway(s) identified in an individual patient and proposed clinical trials. The NEPTUNE Match report is communicated using established protocols to the patient and the attending nephrologist for use in their selection of available clinical trials. NEPTUNE Match represents the first application of precision medicine in nephrology with the aim of developing targeted therapies and providing the right medication for each patient with primary glomerular disease. Glomerular diseases are classified using a descriptive taxonomy that is not reflective of the heterogeneous underlying molecular drivers. This limits not only diagnostic and therapeutic patient management, but also impacts clinical trials evaluating targeted interventions. The Nephrotic Syndrome Study Network (NEPTUNE) is poised to address these challenges. The study has enrolled >850 pediatric and adult patients with proteinuric glomerular diseases who have contributed to deep clinical, histologic, genetic, and molecular profiles linked to long-term outcomes. The NEPTUNE Knowledge Network, comprising combined, multiscalar data sets, captures each participant’s molecular disease processes at the time of kidney biopsy. In this editorial, we describe the design and implementation of NEPTUNE Match, which bridges a basic science discovery pipeline with targeted clinical trials. Noninvasive biomarkers have been developed for real-time pathway analyses. A Molecular Nephrology Board reviews the pathway maps together with clinical, laboratory, and histopathologic data assembled for each patient to compile a Match report that estimates the fit between the specific molecular disease pathway(s) identified in an individual patient and proposed clinical trials. The NEPTUNE Match report is communicated using established protocols to the patient and the attending nephrologist for use in their selection of available clinical trials. NEPTUNE Match represents the first application of precision medicine in nephrology with the aim of developing targeted therapies and providing the right medication for each patient with primary glomerular disease. Nephrotic syndrome (NS) comprises focal segmental glomerular sclerosis (FSGS), minimal change disease, and membranous nephropathy, which are rare glomerular diseases associated with debilitating complications, including possible progression to kidney failure. Despite similar and overlapping symptoms (e.g., edema, proteinuria, and loss of kidney function), individual clinical courses can vary markedly. The only US Food and Drug Administration–approved medical treatments are corticosteroid-based immunosuppressive agents (i.e., prednisone and adrenocorticotrophic hormone) that cause severe adverse effects. Off-label use of second-line immunosuppressive medications is currently part of guideline-based clinical care. The clinical, histopathology-based taxonomy of NS fails to capture the underlying molecular drivers of these diseases (Figure 1). Consequently, current diagnostic categories have limited use in either predicting the disease course or responding to therapy, frequently putting patients at risk of adverse effects from treatments that prove ineffective. In addition, clinical trials in NS enroll an unstratified, biologically diverse group of individuals. This underlying mechanistic heterogeneity often results in inconclusive trial outcomes, even though the intervention may successfully target a subset of susceptible patients. The Nephrotic Syndrome Study Network (NEPTUNE) was developed to define the molecular mechanism of NS for targeted therapeutic interventions. NEPTUNE follows the natural history of patients and aims to improve the diagnosis, management, and treatment of NS using innovative research strategies1Gadegbeku C.A. Gipson D.S. Holzman L.B. et al.Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.Kidney Int. 2013; 83: 749-756Abstract Full Text Full Text PDF PubMed Scopus (218) Google Scholar (Figure 2). Participants are enrolled into NEPTUNE at the time of a diagnostic kidney biopsy or at initial presentation of disease for pediatric patients for whom a biopsy is usually not clinically indicated. In the biopsy cohort, an extra core of kidney tissue is obtained during the clinically indicated procedure for research studies. Blood and urine specimens, along with clinical data, are collected prospectively every 4 to 6 months for up to 5 years. NEPTUNE has recruited a prospective longitudinal observational cohort of 861 patients with proteinuric, glomerular diseases who have contributed deep clinical, histologic, genetic, and molecular data as well as profiles of their long-term outcomes under standard care or in independent clinical trials. A key component of NEPTUNE that was established at its inception was the creation of a dedicated biorepository for long-term storage of the full range of biospecimens collected from each participant.1Gadegbeku C.A. Gipson D.S. Holzman L.B. et al.Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.Kidney Int. 2013; 83: 749-756Abstract Full Text Full Text PDF PubMed Scopus (218) Google Scholar NEPTUNE has continuously enhanced its ability to derive multiscalar data sets robustly and efficiently from the clinical data and biosamples contributed by study participants. This effort has been conducted through approved ancillary studies that leverage the Biorepository and tranSMART database. For example, capture of environmental exposures and socioeconomic status is incorporated into prospective ascertainment of long-term outcomes relevant to glomerular diseases. Kidney biopsy tissue is used for a digital pathology-driven structural definition of the disease state,2Barisoni L. Lafata K.J. Hewitt S.M. et al.Digital pathology and computational image analysis in nephropathology.Nat Rev Nephrol. 2020; 16: 669-685Crossref PubMed Scopus (113) Google Scholar, 3Barisoni L. Nast C.C. Jennette J.C. et al.Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE).Clin J Am Soc Nephrol. 2013; 8: 1449-1459Crossref PubMed Scopus (68) Google Scholar, 4Barisoni L. Troost J.P. Nast C. et al.Reproducibility of the NEPTUNE descriptor-based scoring system on whole-slide images and histologic and ultrastructural digital images.Mod Pathol. 2016; 29: 671-684Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar, 5Hodgin J.B. Mariani L.H. Zee J. et al.Quantification of glomerular structural lesions: associations with clinical outcomes and transcriptomic profiles in nephrotic syndrome.Am J Kidney Dis. 2022; 79: 807-819.e1Abstract Full Text Full Text PDF Scopus (0) Google Scholar, 6Mariani L.H. Martini S. Barisoni L. et al.Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.Nephrol Dial Transplant. 2018; 33: 310-318Crossref PubMed Scopus (64) Google Scholar, 7Nast C.C. Lemley K.V. Hodgin J.B. et al.Morphology in the digital age: integrating high-resolution description of structural alterations with phenotypes and genotypes.Semin Nephrol. 2015; 35: Full Text Full Text PDF PubMed Google Scholar, Zee J. et of proteinuric patients clinical Am Soc Nephrol. 2020; PubMed Scopus Google Scholar, J. et biopsy of clinical outcomes in the of minimal change disease and focal segmental Am Soc Nephrol. 2022; 33: PubMed Scopus Google Scholar et study and in pediatric nephrotic PubMed Scopus Google Scholar, et of the focal segmental and kidney disease. Scholar, et of kidney disease and through high-resolution and Scopus Google Scholar, C.C. Martini S. et associations with risk in NEPTUNE Am Soc Nephrol. 2016; PubMed Scopus Google Scholar, C.C. et glomerular disease a of the Kidney in and Nephrotic Syndrome Study Network (NEPTUNE) Dial Transplant. Google Scholar, et of kidney tissue in nephrotic syndrome.Am J 2018; Full Text Full Text PDF PubMed Scopus Google Scholar profiles from and L.H. S. et nephrology identified in minimal change disease and focal segmental Int. Full Text Full Text PDF PubMed Scopus Google Scholar and Barisoni et the molecular of in kidney disease progression by of transcriptomic analysis and pathology Scholar, et focal segmental 2020; Scopus Google Scholar, et a of glomerular PubMed Scopus Google Scholar and and profiles are to transcriptomic in the L.H. S. et nephrology identified in minimal change disease and focal segmental Int. Full Text Full Text PDF PubMed Scopus Google Troost J.P. et and and tissue and with glomerular disease Dis. Google Scholar, et analysis glomerular in focal segmental Am Soc Nephrol. 2020; PubMed Scopus Google Scholar, S. et of as a kidney disease 2015; PubMed Scopus Google Scholar, S. et and in rare kidney Dis. 2018; Google Scholar The heterogeneous are in the NEPTUNE Knowledge Network for mechanistic disease The NEPTUNE Knowledge Network is by the kidney research a NEPTUNE tranSMART tranSMART the to diverse data sets in an data with and The of currently 861 study patient socioeconomic clinical disease glomerular C.A. Gipson D.S. Holzman L.B. et al.Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach.Kidney Int. 2013; 83: 749-756Abstract Full Text Full Text PDF PubMed Scopus (218) Google Scholar glomerular and data sets, and urine and targeted data, and urine and the NEPTUNE J.B. Mariani L.H. Zee J. et al.Quantification of glomerular structural lesions: associations with clinical outcomes and transcriptomic profiles in nephrotic syndrome.Am J Kidney Dis. 2022; 79: 807-819.e1Abstract Full Text Full Text PDF Scopus (0) Google Scholar profiles from a can in a NEPTUNE and can obtained in the approved ancillary studies have used the NEPTUNE Knowledge Network in of the research in glomerular diseases The NEPTUNE research has that each participant’s data can and molecular profiles in a to a molecular nephrology report for each patient that can communicated to NS in molecular is in precision medicine to therapeutic and improve clinical trial NEPTUNE have using data to disease in of J.B. Mariani L.H. Zee J. et al.Quantification of glomerular structural lesions: associations with clinical outcomes and transcriptomic profiles in nephrotic syndrome.Am J Kidney Dis. 2022; 79: 807-819.e1Abstract Full Text Full Text PDF Scopus (0) Google L.H. S. et nephrology identified in minimal change disease and focal segmental Int. Full Text Full Text PDF PubMed Scopus Google Scholar and in in specific molecular pathway in patients with and J. Mariani L. S. et is in the kidney and of patients with focal segmental Int. 2018; Full Text Full Text PDF PubMed Scopus Google J. Mariani L. S. et in and kidney tissue in J Am Soc Nephrol. 2020; PubMed Scopus Google Scholar have as for patients for targeted therapies and in the first molecular trial in NS L. Lafata K.J. Hewitt S.M. et al.Digital pathology and computational image analysis in nephropathology.Nat Rev Nephrol. 2020; 16: 669-685Crossref PubMed Scopus (113) Google L. Nast C.C. Jennette J.C. et al.Digital pathology evaluation in the multicenter Nephrotic Syndrome Study Network (NEPTUNE).Clin J Am Soc Nephrol. 2013; 8: 1449-1459Crossref PubMed Scopus (68) Google Scholar In in with an of disease has been a in the of clinical trials with clinical trials selection for patients and the of outcomes these trials. This not only the molecular disease of NS to individual therapeutic in a but the of an to of clinical trials that target that may their disease The of NEPTUNE Match is to the implementation of precision medicine in the right trial is available to the right patient at the right a precision medicine can to patients with the 4 have been developed for NEPTUNE Match (Figure individual molecular disease profiles in NEPTUNE study in Match individual molecular disease profiles in the molecular nephrology report with of NS a to study of the Molecular Nephrology Board for targeted trial kidney outcomes in NEPTUNE Match study trial with or A key for NEPTUNE Match is the of biomarkers of the of the specific disease targeted by the biomarkers can used to Match pathway Match disease pathway can from a of molecular in to pathway or therapeutic for the treatment biomarkers the molecular pathway linked to target L.H. S. et nephrology identified in minimal change disease and focal segmental Int. Full Text Full Text PDF PubMed Scopus Google in of of a specific J. Mariani L. S. et is in the kidney and of patients with focal segmental Int. 2018; Full Text Full Text PDF PubMed Scopus Google molecular treatment in (e.g., or urine molecular profiles from and to disease profiles in or molecular profiles from or urine linked to clinically treatment obtained in trials or The NEPTUNE Knowledge Network has clinical and molecular of NEPTUNE to in target and the to define a target for Match profiles with a between NEPTUNE kidney biopsy profiles and which are to the by This target is the cohort to define associations with clinical or histologic and outcomes the study by Mariani et L.H. S. et nephrology identified in minimal change disease and focal segmental Int. Full Text Full Text PDF PubMed Scopus Google Scholar for a and comprising the target in are linked to and profiles from and urine obtained at the time of kidney biopsy to of the In the selection and is to biomarkers in or urine with the of or with the target in profiles in kidney selection of the for and urine as and for specific biosamples standard for Drug and Scholar, et to 2015; PubMed Scopus Google Scholar, et and implementation of the on 2013; PubMed Scopus (0) Google Scholar the profiles the NEPTUNE cohort are and used to a predicting of the kidney to have been of clinical and a of urine biomarkers a example, study design a is and biosamples from patients in the cohort and the of the Match the cohort is patient are a the pathway the NEPTUNE The of the Match is to the Molecular Nephrology Board and used to NEPTUNE Match that the individual pathway in to the NEPTUNE patient (Figure In a study of this NEPTUNE have in In the for a to a to was in a limited of Gipson D.S. L. et trial of in focal segmental (FSGS), report of the for study J Kidney Dis. Full Text Full Text PDF PubMed Scopus (0) Google Scholar, et of trial of and in report of the study Nephrol. PubMed Scopus (0) Google Scholar, S. et of and in patients with focal segmental report of the clinical trial Nephrol. 2015; 16: PubMed Scopus Google Scholar in an clinical trial the that kidney a predictor of a to a was obtained from NEPTUNE kidney biopsy profiles using to on The of the was in kidney L.H. S. et nephrology identified in minimal change disease and focal segmental Int. Full Text Full Text PDF PubMed Scopus Google Scholar and identified as a of of the in NEPTUNE of and identified as with to their kidney for A using and together with glomerular and urine of in with an under the of L.H. S. et nephrology identified in minimal change disease and focal segmental Int. Full Text Full Text PDF PubMed Scopus Google Scholar is used as the primary in an target trial in patients with Match are linked to clinical in NS for 4 studies. of these has Match and For example, the of profiles and urine from the for at of the 4 in with either or minimal change disease (Figure in NEPTUNE Match is to NEPTUNE participants. The of clinical trials in NEPTUNE Match and trials. with NEPTUNE Match, the to trial data to clinical trials that therapeutic that are to and with the molecular of the NEPTUNE are for NEPTUNE Match with and of in is on the and to and as to in NEPTUNE for the NEPTUNE Match trials (e.g., trial is a are not data the disease of NEPTUNE are in NEPTUNE for clinical and have been established to evaluate clinical, histologic, and molecular data to molecular pathway for by the Molecular Nephrology The Molecular Nephrology Board reviews the on the pathway by the NEPTUNE of targeted by clinical trials in NS are for each The proposed of the of each to each trial is to the Molecular Nephrology Board for The Molecular Nephrology Board and the trial and on the Match The Match report is the pathway of the study to the NEPTUNE in The Match report this for each clinical trial for which the patient on specific the in the Match report is and not are to study and NEPTUNE the of the study and the of the analysis and the by and in with a patient has developed and a that with of NEPTUNE Match clinical This and of the NEPTUNE Match report to participants. from the Molecular Nephrology Board trial and are to study by of the NEPTUNE Match The report the of to clinical but also the and research of the in the The creation of NEPTUNE Match follows including of to and use of to of and of of the of the NEPTUNE Match the a for study to the in the report and its for clinical trial and patient care. to in the an of trial is of this for key and on to address from the The of the Match report may the study and of the in to the adult for participants. This a of the initial and of A is the initial to address or that the may the are is an with by the which the participant’s of key during the and L. Troost J.P. Nast C. et al.Reproducibility of the NEPTUNE descriptor-based scoring system on whole-slide images and histologic and ultrastructural digital images.Mod Pathol. 2016; 29: 671-684Abstract Full Text Full Text PDF PubMed Scopus (48) Google Scholar, 5Hodgin J.B. Mariani L.H. Zee J. et al.Quantification of glomerular structural lesions: associations with clinical outcomes and transcriptomic profiles in nephrotic syndrome.Am J Kidney Dis. 2022; 79: 807-819.e1Abstract Full Text Full Text PDF Scopus (0) Google Scholar, 6Mariani L.H. Martini S. Barisoni L. et al.Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies.Nephrol Dial Transplant. 2018; 33: 310-318Crossref PubMed Scopus (64) Google Scholar, 7Nast C.C. Lemley K.V. Hodgin J.B. et al.Morphology in the digital age: integrating high-resolution description of structural alterations with phenotypes and genotypes.Semin Nephrol. 2015; 35: Full Text Full Text PDF PubMed Google Scholar, Zee J. et of proteinuric patients clinical Am Soc Nephrol. 2020; PubMed Scopus Google Scholar, J. et biopsy of clinical outcomes in the of minimal change disease and focal segmental Am Soc Nephrol. 2022; 33: PubMed Scopus Google Scholar, et study and in pediatric nephrotic PubMed Scopus Google Scholar, et of the focal segmental and kidney disease. Scholar is a used in research and care is communicated to the and the is to The in this can as is using and by of the report with are to in their this to at or for and are to their This is the of the as or full for each of The possible from to The of the NEPTUNE is using established is a that has been from the et and PubMed Scopus Google Scholar is used to the of to patients in research and clinical with from the and of and to The an of the to evaluate the of the NEPTUNE Match this of the of molecular with as a of patients. the by the Match report may in and The of a of the of the J PubMed Google Scholar is a used and is used in to a participant’s symptoms at the and the for of the for results of enrolled in trials with an trial with or to the of Match on treatment NEPTUNE Match not enroll patients into clinical trials. its is to a report that the of between a underlying disease and the mechanism of of a under evaluation in a clinical is to a to disease to patients and in their the trial for The in a Match trial is by the patient and attending who may or may not a NEPTUNE patients a the patient and for are by the trial The of the trial for the and individual NEPTUNE Match trial outcomes to NEPTUNE for analysis on of the The of NEPTUNE Match by a analysis of outcomes in trials. the of we can to the of treatment (e.g., of with at 4 on J.P. et definition of in focal segmental J Am Soc Nephrol. 2018; PubMed Scopus Google Scholar between trial with trial to with that trials in the Match of or with or primary capture and glomerular at a time to clinical outcome current data that a of is this a of that of are on therapies for which their molecular is and that are to and and using a we have at to group of between outcome in patients who are a trial treatment to treatment of to for example, we have to a of treatment in treatment in participants. the by trials with we also for individual trials in the Match a study as an and using the we have at to group of with treatment of to for example, we have to a of treatment for and treatment for in a trial of participants. we to treatment as the change from in urine that we to as we with the Match NEPTUNE Match is a trials and associated biomarkers of NS disease to developed and to the of available clinical trials. the between and the clinical trials in Match, the NEPTUNE was The NEPTUNE as a for of targeted in clinical by the or with In Match to the to the of a heterogeneous of patients to clinical trials with an the of to the disease in the individual In NEPTUNE Match patient by providing with to the molecular of their disease that can use evaluating in available clinical trials. has developed a for a of primary glomerular diseases that to precision medicine therapeutic a key in NEPTUNE Match, profiles have been developed to patients with of kidney on of the kidney This is a key in basic science glomerular diseases into application for patient Match, a has been to evaluate the molecular in individual patients in a and with clinical and molecular targeted therapies are developed in NEPTUNE to the the Match NEPTUNE has been and to the research that from the Match evaluation to patients to of the results and use as in prospective clinical trials. of disease processes to evaluate in clinical in are this by as to nephrotic syndrome in and to the effects of proposed L.H. S. et nephrology identified in minimal change disease and focal segmental Int. Full Text Full Text PDF PubMed Scopus Google J. C.C. et of kidney Scopus (0) Google Scholar data clinical of the natural history of the primary glomerular and in Match to of each the in and the of precision medicine in nephrology in and glomerular diseases in to of to of Match and to of patients to NEPTUNE for in this research an for to patients to their of precision medicine in nephrology and to to their key is disease to to can to kidney are to with patient to with and clinical that Match profiles can in of clinical trial NEPTUNE Match represents an multidisciplinary effort to precision medicine for the of clinical trials for patients with kidney disease, primary glomerular represents the first the of providing the right treatment in the for each individual Match is in the and has key that are for the long-term of this to the we to improve the and nephrology with a on precision of and storage of biospecimens collected during medical care and clinical trial that patients can for precision clinical trials in a prospective for with trials that in the the of with and the discovery pipeline to define therapeutic and in individual patients. In addition, the of therapeutic available to patients and with on adverse and of therapies in clinical trials. NEPTUNE Match an to an of that have the and to trials of innovative precision that NEPTUNE Match as a for the design and implementation of trial as and and J.P. et of trials the of trials on clinical 2022; Scopus Google Scholar that the evaluation of therapeutic In with may to of targeted therapies for susceptible patients and these agents into and studies. with patient and and nephrology can the and of precision medicine for kidney disease. a clinical can precision medicine trials in an to the of the full range of from pediatric to by primary glomerular diseases. The the nephrology to therapeutic to glomerular disease is of the of research in we have a of data, and in to treatments to patients. from of from of through the of from and as well as and the through the of with the and through the of from and and on the for and the Kidney In addition, and have a and for for Kidney with has with Board for pediatric and and for in glomerular disease by and is on the and Board for of in and Study of the and of in the of for is a of the Kidney Board of an of Glomerular and and as a with Kidney in to pediatric in clinical trials for glomerular diseases current from the of and and Kidney and from from and and a on is also on the and clinical trials of the of Glomerular to this from and and through the of research from the for and US Food and Drug and to the of from and in for the the of Kidney Network and the of the Kidney in the kidney disease the of the Kidney nephropathy the of the Kidney outcomes and the for the and Kidney to for in pediatric from the of current has from the through the of from from the of and is a of the of from the and Kidney in of this and Network, and of this has or from from for for Kidney and and the of Kidney The Kidney has and from by the and and is a on the study and to this is a on the of the of and on the of the of from the and the in of this and from and to this study through the of has on the of and and for and as an Board or for was by from for this of this from and is an of and trials and of the of the The Nephrotic Syndrome Study Network (NEPTUNE) is part of the Network by the of and by the for through its of NEPTUNE is under a between and the of and and Kidney is by the of Kidney Syndrome and the are by the and by and the of and under This study was also in part through research from and of the Nephrotic Syndrome Study Network (NEPTUNE) The of The of at of Network of at of of of of of of of of of of in of for of of of Hewitt Hodgin of Mariani of of of of of of Zee of of Barisoni Nast

  PublisherOA PDFDOI

• Major Adverse Cardiovascular Events (MACE) in Proteinuric Glomerulopathies: A CureGN and NEPTUNE Study

  Journal of the American Society of Nephrology · 2024-10-01

  article
  PublisherDOI

• Growth in children with nephrotic syndrome: a post hoc analysis of the NEPTUNE study

  Pediatric Nephrology · 2024-04-26

  articleOpen access
  PublisherOA PDFDOI

• Ancestral diversity improves discovery and fine-mapping of genetic loci for anthropometric traits—The Hispanic/Latino Anthropometry Consortium

  UNC Libraries · 2024-02-10

  articleOpen access

  Hispanic/Latinos have been underrepresented in genome-wide association studies (GWAS) for anthropometric traits despite their notable anthropometric variability, ancestry proportions, and high burden of growth stunting and overweight/obesity. To address this knowledge gap, we analyzed densely imputed genetic data in a sample of Hispanic/Latino adults to identify and fine-map genetic variants associated with body mass index (BMI), height, and BMI-adjusted waist-to-hip ratio (WHRadjBMI). We conducted a GWAS of 18 studies/consortia as part of the Hispanic/Latino Anthropometry (HISLA) Consortium (stage 1, n = 59,771) and generalized our findings in 9 additional studies (stage 2, n = 10,538). We conducted a trans-ancestral GWAS with summary statistics from HISLA stage 1 and existing consortia of European and African ancestries. In our HISLA stage 1 + 2 analyses, we discovered one BMI locus, as well as two BMI signals and another height signal each within established anthropometric loci. In our trans-ancestral meta-analysis, we discovered three BMI loci, one height locus, and one WHRadjBMI locus. We also identified 3 secondary signals for BMI, 28 for height, and 2 for WHRadjBMI in established loci. We show that 336 known BMI, 1,177 known height, and 143 known WHRadjBMI (combined) SNPs demonstrated suggestive transferability (nominal significance and effect estimate directional consistency) in Hispanic/Latino adults. Of these, 36 BMI, 124 height, and 11 WHRadjBMI SNPs were significant after trait-specific Bonferroni correction. Trans-ancestral meta-analysis of the three ancestries showed a small-to-moderate impact of uncorrected population stratification on the resulting effect size estimates. Our findings demonstrate that future studies may also benefit from leveraging diverse ancestries and differences in linkage disequilibrium patterns to discover novel loci and additional signals with less residual population stratification.

  PublisherDOI

• Morphological Changes in a Nephrectomized End-Stage Kidney 10 Years after Hemodialysis (HD) Initiation for Atypical Hemolytic Uremic Syndrome (aHUS)

  Journal of the American Society of Nephrology · 2024-10-01

  articleSenior author
  PublisherDOI

• Associations between APOL1 Genotypes and Major Adverse Cardiovascular Events (MACE) in Proteinuric Glomerulopathies: A CureGN and NEPTUNE Study

  Journal of the American Society of Nephrology · 2024-10-01

  article
  PublisherDOI

• Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy

  Kidney International Reports · 2024-06-20 · 24 citations

  articleOpen access

  Introduction: Primary membranous nephropathy (PMN) is most often caused by autoantibodies to phospholipase A2 receptor (PLA2R). M-PLACE (NCT04145440) is an open-label, phase 1b/2a study that assessed the safety and efficacy of the fully human anti-CD38 monoclonal antibody felzartamab in high-risk anti-PLA2R+ PMN. Methods: = 13) received 9 infusions of felzartamab 16 mg/kg in the 24-week treatment period, followed by a 28-week follow-up. The primary end point was the incidence and severity of treatment-emergent adverse events (TEAEs). Results: A total of 31 patients were enrolled and received felzartamab. Twenty-seven patients (87.1%) had TEAEs, including infusion-related reactions (IRRs) (29.0%), hypogammaglobulinemia (25.8%), peripheral edema (19.4%), and nausea (16.1%). Five patients (16.1%) had serious TEAEs that all resolved. Immunologic response (anti-PLA2R titer reduction ≥50%) was achieved by 20 of 26 efficacy-evaluable patients (76.9%) (C1, 13/15 [86.7%]; C2, 7/11 [63.6%]). Anti-PLA2R titer reductions were rapid (week 1 response, 44.0%; response 7 months after last felzartamab dose [end of study, EOS], 53.8%). Partial proteinuria remission (urine protein-to-creatinine ratio [UPCR] reduction ≥50%, UPCR <3.0 g/g, and stable estimated glomerular filtration rate [eGFR]) was achieved by 9 of 26 patients (34.6%) (C1, 7/15 [46.7%]; C2, 2/11 [18.2%]) before or at EOS (median follow-up, 366 days). Serum albumin increased from baseline to EOS in 20 of 26 patients (76.9%) (C1, 12/15 [80.0%]; C2, 8/11 [72.7%]). Conclusion: In this population with high-risk anti-PLA2R+ PMN, felzartamab was tolerated and resulted in rapid partial and complete immunologic responses and partial improvements in proteinuria and serum albumin in some patients.

  PublisherOA PDFDOI

Recent grants

• NIH Grant U01DK057249

  NIH · $2.6M · 2006

• NIH Grant R29DK038451

  NIH · $450k · 1995

• NIH Grant R21AT002945

  NIH · $471k · 2009

• NIH Grant M01RR000425

  NIH · $45.7M · 2011

• NIH Grant R01DK069844

  NIH · $2.1M · 2010

Frequent coauthors

• Cynthia C. Nast

  Cedars-Sinai Medical Center

  200 shared

• Michelle Hladunewich

  The Ohio State University Wexner Medical Center

  166 shared

• Janine LaPage

  164 shared

• Lawrence B. Holzman

  University of Pennsylvania

  162 shared

• John R. Sedor

  160 shared

• Heather N. Reich

  University of Toronto

  159 shared

• Katherine R. Tuttle

  Providence Health & Services

  147 shared

• Debbie S. Gipson

  National Institute of Diabetes and Digestive and Kidney Diseases

  133 shared

Labs

• EthnomusicologyPI